Zhou, Royce W.
Xu, Jia
Martin, Tiphaine C. http://orcid.org/0000-0001-9990-1455
Zachem, Alexis L.
He, John
Ozturk, Sait
Demircioglu, Deniz http://orcid.org/0000-0001-7857-0407
Bansal, Ankita
Trotta, Andrew P.
Giotti, Bruno
Gryder, Berkley http://orcid.org/0000-0003-0130-2302
Shen, Yao
Wu, Xuewei
Carcamo, Saul
Bosch, Kaitlyn
Hopkins, Benjamin http://orcid.org/0000-0002-7970-6430
Tsankov, Alexander http://orcid.org/0000-0002-7955-4414
Steinhagen, Randolph
Jones, Drew R.
Asara, John
Chipuk, Jerry E.
Brody, Rachel
Itzkowitz, Steven
Chio, Iok In Christine http://orcid.org/0000-0002-3635-2679
Hasson, Dan
Bernstein, Emily http://orcid.org/0000-0001-6533-8326
Parsons, Ramon E. http://orcid.org/0000-0002-6656-3514
Article History
Received: 26 April 2022
Accepted: 15 September 2022
First Online: 17 October 2022
Change Date: 6 April 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-023-37640-4
Competing interests
: R.E.P. owns equity in Therapten. Ramon Parsons receives royalty payments from Cullgen and Therapten. R.E.P. gives industry-sponsored lectures at the Lurie Cancer Center and the University of Southern California Cancer Center. R.E.P. reports other activities with Columbia University and Regeneron Pharmaceuticals. S.H.I. consults for EXACT Sciences Corporation, and Geneoscopy. S.H.I. receives royalty payments from Bio-Rad Laboratories Inc. The remaining authors declare no competing interest.